Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Strengthens Sunscreen Testing And Label Requirements

This article was originally published in The Tan Sheet

Executive Summary

As early as June 2012, sunscreens that fail “broad spectrum” tests or have an SPF less than 15 must warn that they have not been shown to prevent cancer or early skin aging, according to an FDA final rule.
Advertisement

Related Content

Spray Sunscreens Stay In FDA Enforcement Discretion Shade
CHPA: Sunscreen Efficacy Ceiling Is More Harmful Than SPF Claim Limit
Industry Needs More Time To Comply With Sunscreen Testing, Labeling Rule
Proposed Spray Sunscreen Warnings A Gateway For Nano Tort Litigation?
FDA Questions Spray Sunscreen Safety, Efficacy And Monograph Status
FDA Considers Capping SPF Values At 50+ Despite Efficacy Data
FDA Considers Capping SPF Values At 50+ Despite Efficacy Data
Hill In Brief
Nanotech May Bring "Unpredictable Changes" To Sunscreen - Report
Sunscreen Proposed Rule May Create UVA Protection Marketing Opportunity
Advertisement
UsernamePublicRestriction

Register

PS105124

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel